Stocks finish higher Tuesday as the Federal Reserve begins its two-day policy meeting amid bets on faster and deeper near-term rate hikes.

"I will be leaving at a time of promise for Biogen, with noteworthy potential for value creation," said departing CEO Michel Vounatsos.

A Medicare policy decision might hurt sales of this biotech giant's Alzheimer's drug.

Biogen will stop developing a drug to treat a severe neurodegenerative disease, as it did not show sufficient benefit when tested in trials.

A brief snapshot of some medical breakthroughs that are among the costliest in the world.

Stocks end sharply lower Thursday as Meta Platform's $200 billion drags tech stocks deeply in the red.

Wall Street will navigate a series of key S&P 500 earnings Thursday as investors look to forward projections from a host of companies amid concerns of rising inflation, Federal Reserve rate hikes and slowing consumer growth.

Stock futures slide as Meta earnings miss ripples through tech sector; Facebook parent shares plunge as TikTok nabs users, rattles Zuckerberg; Spotify shares tumble as user forecasts hit by 'Joe Rogan' fallout; Amazon earnings on deck with labor and shipping costs in focus and Tesla is back in the crosshairs of the NHTSA.

Shares of Biogen gapped down on Wednesday on negative news for its Alzheimer's drug. But that could give bulls an opportunity.

Surging U.S. output, set against fading demand from China, as global oil prices on the back foot again Monday and adding further downward pressure to domestic gas prices.

“Oyu Tolgoi is an attractive tier one asset, and we remain highly focused on and optimistic about its transformation into one of the world’s great copper mines," Turquoise Hill said.

The National Highway Transit Safety Administration received over 50 complaints over brake hose ruptures.